Vascular Protection by Ketanserin, a 5-HT(2) Serotonergic Receptor Antagonist?

Based upon experimental data, we advance the hypothesis that ketanserin, a 5-HT(2) serotonergic receptor antagonist, may provide protection against pathologies resulting from platelet-vessel wall interactions such as myointimal proliferation, vasospasms and thrombus formation. Clinical data support the possibility that such a vascular protection is operational also in man.

Ketanserin in the treatment of peripheral vascular disease or hypertension in patients with diabetes mellitus: a review.

The available data on the use of ketanserin in diabetes mellitus have been reviewed. Ketanserin does not worsen glucose tolerance or destabilize diabetic control. Ketanserin can improve impairment of peripheral blood flow, and especially skin blood flow; the healing of cutaneous ulcers is improved; trophic skin changes are fewer; and there is a trend towards less limb amputations.

Ketanserin: a novel cardiovascular drug.

Ketanserin is the archetype of a new class of cardiovascular drugs, the 5HT2 (S2) serotonergic receptor antagonists. In humans, ketanserin inhibits serotonin-induced vasoconstriction and platelet activation. In addition, it reduces platelet hyperactivity, blood viscosity and total serum cholesterol.